Clinical guideline SEOM: hepatocellular carcinoma

Clinical and Translational Oncology

Volumn 17, Issue 12, 2015, Pages 988-995

  Sastre, J ^a   Diaz Beveridge R ^b   Garcia Foncillas J ^c   Guardeno R ^d   Lopez C ^e   Pazo, R ^f   Rodriguez Salas, N ^g   Salgado, M ^h   Salud, A ⁱ   Feliu, J ^g  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^d HOSPITAL JOSEP TRUETA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h Medical Oncology Department   (Spain)

ⁱ Hospital Arnau de Villanova   (Spain)

Author keywords

Ablative therapies; Guidelines; Hepatocellular carcinoma; Sorafenib

Indexed keywords

FORETINIB; RAMUCIRUMAB; SORAFENIB; TIVANTINIB;

ABLATION THERAPY; ARTICLE; BIOPSY; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CHRONIC HEPATITIS C; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; FIBROSIS; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; STEREOTACTIC BODY RADIATION THERAPY; CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; EARLY CANCER DIAGNOSIS; LIVER NEOPLASMS; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; PRACTICE GUIDELINE; PROGNOSIS; STANDARDS;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SOCIETIES, MEDICAL;

EID: 84952873526     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1451-3     Document Type: Article

References (37)

1. GLOBOCAN 2012. Estimated cancer incidence, prevalence and mortality worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
2. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44(Suppl 19):89.
3. Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int. 2014;111:101–6.
4. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.
5. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.
6. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–9.
7. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology. 2003;38:1034–42.
8. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49:658–64.
9. Marrero JA, Kudo M, Bronowicki J. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15(Suppl 4):23–33.
10. Duseja A. Staging of hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S74–9. doi:10.1016/j.jceh.2014.03.045.
11. Addissie BD, Roberts LR. Classification and staging of hepatocellular carcinoma. Clin Liver Dis. 2015;19(2):277–94. http://linkinghub.elsevier.com/retrieve/pii/S1089326115000124.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
13. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection vs. transplantation. Hepatology. 1999;30:1434–40.
14. Bruix J, Takayama T, Mazzaferro V, Chau G-Y, Yang J, Kudo M, et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol. 2014;32:5s (suppl; abstr 4006).
15. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247:49–57.
16. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255:405–14.
17. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2014;61:82–8.
18. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.
19. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg. 2003;238:508–18.
20. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599–641.
21. Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7(12):1632–51.
22. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.
23. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255.
24. Lo C-M, Ngan H, Tso W-K, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.
25. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.
26. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35:1119–28.
27. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117.
28. Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359.
29. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21:224.
30. Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82:2004.
31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J. 2008;359(4):378–90.
32. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
33. Suzuki E, Chiba T, Ooka Y, Ogasawara S, Tawada A, Motoyama T, et al. Transcatheter arterial infusion for advanced hepatocellular carcinoma: who are candidates? World J Gastroenterol. 2015;21(29):8888–93.
34. Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70.
35. Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: a review. World J Gastroenterol. 2015;21(18):5445–53.
36. Rimassa L, Santoro A, Daniele B, Germano D, Gasbarrini A, Salvagni S, et al. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers. Tumori. 2015;101(2):139–43.
37. Hatzaras I, Bischof DA, Fahy B, Cosgrove D, Pawlik TM. Treatment options and surveillance strategies after therapy for hepatocellular carcinoma. Ann Surg Oncol. 2014;21:758–66.